Cargando…

Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

Detalles Bibliográficos
Autores principales:	Hahn, Timothy, Daymont, Carrie, Beukelman, Timothy, Groh, Brandt, Hays, Kimberly, Bingham, Catherine April, Scalzi, Lisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Publisher Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749320/ https://www.ncbi.nlm.nih.gov/pubmed/36517887 http://dx.doi.org/10.1186/s12969-022-00775-7

Ejemplares similares

Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

An assessment of variables affecting transition readiness in pediatric rheumatology patients
por: Bingham, Catherine April, et al.
Publicado: (2015)

Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Mannion, Melissa L., et al.
Publicado: (2022)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
por: Beukelman, Timothy, et al.
Publicado: (2022)

The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months
por: Beukelman, Timothy, et al.
Publicado: (2017)

Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
por: Kimura, Yukiko, et al.
Publicado: (2017)

Med-peds rheumatology in practice: assessment after twenty years
por: Ostrov, Barbara E, et al.
Publicado: (2012)

Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
por: Prahalad, Sampath, et al.
Publicado: (2016)

Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus
por: Ota, Sylvia, et al.
Publicado: (2008)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
por: Gerardi, Maria Chiara, et al.
Publicado: (2022)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
por: van Vollenhoven, Ronald F, et al.
Publicado: (2023)

Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey
por: Shenoi, Susan, et al.
Publicado: (2019)

Treatment advances in systemic juvenile idiopathic arthritis
por: Beukelman, Timothy
Publicado: (2014)

Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Henderson, Lauren A., et al.
Publicado: (2016)

Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
por: Aljohani, Roaa, et al.
Publicado: (2021)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Translating research into practice—implementation recommendations for pediatric rheumatology; Proceedings of the childhood arthritis and rheumatology research alliance 2020 implementation science retreat
por: Yildirim-Toruner, Cagri, et al.
Publicado: (2022)

The childhood arthritis & rheumatology research alliance network registry: demographics and characteristics of the initial 6-month cohort
por: Natter, Marc D, et al.
Publicado: (2012)

Association of Race and Ethnicity With Medication Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Roberts, Jordan E., et al.
Publicado: (2022)

Proceedings of the 2016 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting: Toronto, Canada. 14-17 April 2016
por: Fotis, Lampros, et al.
Publicado: (2016)

Neuroblastoma versus systemic JIA – a diagnostic dilemma
por: Scalzi, Lisabeth, et al.
Publicado: (2012)

Intraarticular overexpression of Smad7 ameliorates experimental arthritis
por: Chen, Shih-Yao, et al.
Publicado: (2016)

Temporomandibular joint arthritis in patients with non-JIA childhood arthritis
por: Cron, Randy Q, et al.
Publicado: (2012)

Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
por: Machold, Klaus P, et al.
Publicado: (2006)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
por: Rintelen, Bernhard, et al.
Publicado: (2016)

Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease
por: Kim, Susan, et al.
Publicado: (2017)

Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Wu, Eveline Y., et al.
Publicado: (2019)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2011)

Erratum to: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
por: Rintelen, Bernhard, et al.
Publicado: (2016)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America
por: Spencer, CH, et al.
Publicado: (2017)

Access to Care and Diagnostic Delays in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Neely, Jessica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oeebau6ncp23rb5jgb0fedlbiv